Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 930Neoplasms 708Prostatic Neoplasms 490Lung Neoplasms 398Carcinoma, Non-Small-Cell Lung 359Colorectal Neoplasms 357Leukemia, Myeloid, Acute 290Pancreatic Neoplasms 238Brain Neoplasms 227Neoplasm Metastasis 221Multiple Myeloma 214Carcinoma, Hepatocellular 199Head and Neck Neoplasms 182Glioblastoma 181Precursor Cell Lymphoblastic Leukemia-Lymphoma 177Melanoma 173Ovarian Neoplasms 168Squamous Cell Carcinoma of Head and Neck 160Uterine Cervical Neoplasms 144Rectal Neoplasms 144Recurrence 142Hematologic Neoplasms 134Sarcoma 133Triple Negative Breast Neoplasms 127Stomach Neoplasms 127Glioma 126Carcinoma, Renal Cell 123Colonic Neoplasms 113Myelodysplastic Syndromes 112Urinary Bladder Neoplasms 109

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Nivolumab 1Leuprolide 1Goserelin 1Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hormone Sensitive Prostate Cancer × 90 days × Clear all
NCT04126070 2026-05-27

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
47 enrolled 16 charts
Genitourinary

Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡